These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [Humanized respiratory syncytial virus monoclonal antibody].
    Author: Tsutsumi H.
    Journal: Nihon Rinsho; 2002 Mar; 60(3):487-91. PubMed ID: 11904963.
    Abstract:
    Respiratory syncytial virus remains a significant cause of severe lower respiratory tract disease in children. The risk of serious RSV illness is highest among children with prematurity, chronic lung disease and congenital heart disease. No effective vaccine and anti-viral agents have been obtained even now. Therefore, conservative therapy including respiratory aid has been a principal therapy for serious RSV disease. Recently, monthly intramuscular administration of humanized anti-RSV monoclonal antibody(palivizumab) was introduced in clinical fields in USA and Europe. Palivizumab prophylaxis has appeared to be safe and effective for prevention of serious RSV illness in premature children and those with bronchopulmonary dysplasia.
    [Abstract] [Full Text] [Related] [New Search]